Mounjaro Lawsuit 2026: 4,025 Cases Pending, New Vision-Loss MDL — Do You Qualify?

Mounjaro lawsuits are active in federal court in 2026. Roughly 4,025 gastrointestinal-injury cases are pending in MDL 3094, and a separate vision-loss docket — MDL 3163 — now holds 247 claims. No settlement program has been announced. If Mounjaro left you with stomach paralysis, an intestinal blockage, or vision loss, you may still be able to file.

Key Facts

  • 4,025 cases pending in MDL 3094 (gastrointestinal injuries) as of October 1, 2026, per the Judicial Panel on Multidistrict Litigation.
  • 247 claims pending in the separate vision-loss docket, MDL 3163, as of October 1, 2026.
  • U.S. District Judge Karen S. Marston (Eastern District of Pennsylvania) presides over both dockets; a multi-day Daubert hearing on expert testimony ran September 14–18, 2026, with no ruling yet.
  • No bellwether trial date has been set and no settlement program announced in either MDL.
  • Mounjaro is tirzepatide, made by Eli Lilly and FDA-approved in 2022 for type 2 diabetes; on August 27, 2026, Lilly updated its label on pancreatic-enzyme risk.

What Is the Mounjaro Lawsuit About?

Mounjaro (tirzepatide) is an injectable drug made by Eli Lilly, first approved for type 2 diabetes and now widely used for weight loss. It belongs to the GLP-1 family: drugs that mimic gut hormones to lower blood sugar and slow digestion — which is precisely where the trouble starts.

Thousands of patients allege Mounjaro caused severe injuries — stomach paralysis, intestinal blockages, blood clots, sudden vision loss — and that Lilly failed to warn adequately. The federal cases are consolidated as a multidistrict litigation (MDL): similar lawsuits grouped before one judge for pretrial proceedings, while each plaintiff’s case keeps its own value.

MDL 3094: Where Things Stand in October 2026

MDL 3094 covers GLP-1 gastrointestinal-injury claims — Mounjaro alongside Ozempic, Wegovy, Rybelsus, and Trulicity — in the Eastern District of Pennsylvania. As of October 1, 2026, 4,025 cases were pending.

The docket is in a decisive phase: Judge Marston held a multi-day Daubert hearing September 14–18, 2026 on whether plaintiffs’ expert testimony on warnings and causation is reliable enough for trial — no ruling yet. Competing summary-judgment motions are pending, and status conferences run through December 15, 2026. For context on the wider litigation family, see our guide to the Ozempic intestinal-blockage lawsuits.

The Vision-Loss Cases Got Their Own MDL

On December 19, 2025, the Judicial Panel created MDL No. 3163 for claims that GLP-1 drugs cause permanent vision loss from NAION (non-arteritic anterior ischemic optic neuropathy) — sudden vision loss from reduced blood flow to the optic nerve. The panel rejected Eli Lilly’s request to fold these cases into MDL 3094 and assigned the new docket to Judge Marston as well.

As of October 1, 2026, MDL 3163 held 247 claims, up 31 in a month. An August 2026 observational study of U.S. insurance data found diabetes patients starting a GLP-1 had an increased — though still rare — risk of ischemic optic neuropathy within 18 months.

Which Injuries Qualify?

Law firms are investigating Mounjaro claims involving: gastroparesis (stomach paralysis — the stomach empties far too slowly, causing relentless nausea, vomiting, and malnutrition); ileus and intestinal blockage requiring hospitalization or surgery; daily vomiting lasting at least three weeks; NAION-related vision loss or blindness; blood clots including deep vein thrombosis and pulmonary embolism; pancreatitis; and certain gallbladder conditions.

Documentation matters: emergency-room records, gastroenterology or ophthalmology diagnoses, and imaging confirming the injury. If you were hospitalized for a blockage or treated for sudden vision changes while on Mounjaro, preserve every record.

Who Can File? The Checklist

You may have a claim if: (1) you were prescribed Mounjaro (tirzepatide) — for diabetes or off-label for weight management; (2) you developed a qualifying injury afterward; (3) your records document the timing; and (4) you are within your state’s filing deadline.

The reason for the prescription generally does not control eligibility — the cases focus on the injury and the warning, not on why your doctor prescribed it. Family members of deceased patients may bring wrongful-death claims under separate state deadlines.

Why 2026 Matters — and What Happens After You File

2026 is the phase that shapes everything after it: the Daubert ruling decides which expert opinions reach a jury, and the bellwether process that follows will test-drive representative cases and set the settlement value of the docket — as pharmaceutical mass torts from Risperdal to Xarelto have shown. But none of that pauses your personal deadline: statutes of limitations run on state law — commonly one to three years from discovery of the injury — regardless of where the MDL stands.

It starts with a free case evaluation; our overview of how to choose a Mounjaro lawyer covers the questions to ask. Reputable firms work on a contingency fee — a percentage of any recovery, nothing owed if you lose; get it in writing. Your case then joins the coordinated proceedings: plaintiff fact sheet, discovery, and positioning for the bellwether and settlement phases. One blunt fact: no settlement program has been announced, compensation varies widely by case, and most settlements are confidential.

Who Benefits From This — and Who Does Not

The Mounjaro lawsuits in 2026 — 4,025 cases pending in MDL 3094 and 247 claims in the separate vision-loss docket MDL 3163, both as of October 1, 2026 — matter to people with a qualifying injury and records showing the timing, not to everyone who simply took the drug.

Who benefits:

  • People prescribed Mounjaro who then developed a qualifying injury: law firms are investigating gastroparesis (stomach paralysis), ileus and intestinal blockage requiring hospitalization or surgery, daily vomiting lasting at least three weeks, and NAION-related vision loss.
  • People who took it for weight loss rather than diabetes: the reason for the prescription generally does not control eligibility; the cases focus on injury, timing, and the state deadline.
  • People who understand the phase the cases are in: the September 14-18, 2026 Daubert hearing and the bellwether process that follows will decide which expert opinions reach a jury and set the docket's settlement value.

Who benefits little or not at all:

  • People with no qualifying injury or no records documenting timing: without an injury after prescription and records showing when it developed, there is nothing for a firm to evaluate.
  • People outside their state's filing deadline: the personal deadline keeps running even while the Daubert and bellwether phases proceed.
  • People expecting a settlement already: as of October 2026, no global settlement program has been announced in MDL 3094 or MDL 3163.

Related reading: Ozempic Ileus Lawsuit 2026: Intestinal Blockage and the FDA Warning.

Frequently Asked Questions

Has there been a Mounjaro settlement?

No. As of October 2026, no global settlement program has been announced in MDL 3094 or MDL 3163. Both dockets are in pretrial proceedings — expert hearings, summary-judgment motions, and preparation for an eventual bellwether process.

I took Mounjaro for weight loss, not diabetes. Can I still sue?

Possibly. The lawsuits focus on the injury and whether Lilly’s warnings were adequate — not on the reason your doctor prescribed the drug. A lawyer will review your prescription history, your diagnosis, and the timing between them.

What is the deadline to file a Mounjaro lawsuit?

Deadlines are set by each state’s statute of limitations, commonly one to three years from when you discovered — or reasonably should have discovered — the injury. Because the clock varies by state and by claim type, get a case review promptly rather than guessing.

How much does a Mounjaro lawyer cost?

Typically nothing upfront. Mass-tort firms handle these cases on a contingency fee — a percentage of any recovery, with nothing owed if the case loses. Ask for the exact percentage in writing before you sign anything.

Who benefits from the Mounjaro lawsuit in 2026 — and who does not?

People who can benefit are those prescribed Mounjaro who then developed a qualifying injury — such as gastroparesis, intestinal blockage requiring hospitalization or surgery, daily vomiting for at least three weeks, or NAION-related vision loss — with records documenting the timing and within their state's deadline. Those who cannot benefit include people with no qualifying injury, no timing records, or an expired state deadline.

How do I start a Mounjaro lawsuit?

Work through the article's checklist: a Mounjaro prescription for diabetes or off-label for weight management, a qualifying injury afterward, records documenting the timing, and a filing within your state's deadline. These cases are almost always handled on contingency, so get the exact percentage in writing before you sign anything.

More plain-English case explainers: Problem Solved on YouTube.

General information only — not legal advice. Laws and deadlines differ by state; consult a qualified attorney.

Watch on YouTube

Problem Solved on YouTube